HAYWARD, Calif., Jan. 9, 2012 /PRNewswire/ -- GenturaDx today announced that its board of directors has appointed a new member, Michael Treble, who is currently chairman and CEO of Axela, Inc. The five current directors, Joe Tian of DT Capital, Min Cui of Bay City Capital, Steve Yu, company founder, Jesus Ching, co-founder and CSO, and Mark Bagnall, CEO will remain on the board.
"The addition of Mike will further diversify the talents and experience that our directors already bring to GenturaDx," said Min Cui, lead director of GenturaDx. "He is a respected and experienced business leader, and will provide our board and management team with new insight and perspectives relating to our business and company building activities."
"Mike has a proven track record of building and realizing value in emerging diagnostic companies. I look forward to working closely with him as we build GenturaDx," said Mark Bagnall, president and CEO.
About Michael Treble
Michael (Mike) Treble is currently the CEO and Chairman of Axela Biosciences, Inc. Treble was past President of Ibis BioSciences, Inc., a molecular infectious disease platform company. Ibis was acquired by Abbott Molecular Diagnostics in January 2009. Previously, Treble was President and CEO of NimbleGen Systems, Inc. Previous positions include EVP, COO and Director of Third Wave Technologies, Inc. and Marketing positions at Roche Diagnostics and Abbott Diagnostics. Treble holds a B.S. degree from Canisius College and a MBA from the University of Buffalo.
GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time PCR amplification and detection, reducing the risk of contamination and saving time. The platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test. For more information, go to www.GenturaDx.com.